Mobile website
Clinical Research
Efficacies of capecitabine combined with irinotecan or rhendostatin for treatment of oxaliplatinresistant patients with advanced colorectal cancer
- Article
- Figures
- Metrics
- Preview PDF
- Reference
- Related
- Cited by
- Materials
Abstract:
Objective: To evaluate the efficacy and safety of capecitabine combined with irinotecan or rhendostatin（endostar）for the treatment of oxaliplatinresistant patients with advanced colorectal cancer. Methods: Fortyfive patients with oxaliplatinresistant advanced colorectal cancer were included in this study. Twentyfive of them were treated with capecitabine combined with irinotecan and 20 of them were treated with capecitabine combined with endostar. Results:The followup period was 321 months. The response rate(RR) was 32.0% in irinotecan treated patients; the clinical benefit rate (CBR) was 72.0%; time of tumor progression (TTP) was 6.2 (95％CI: 3.125~8.905) months. The RR was 55.0% in endostar treated patients; the CBR was 90.0% and TTP was 10.6 (95％CI: 7.876~12.962) months. There was significant difference between the two groups concerning the above three parameters (P<0.05). The overall survival periods (OS) of the two groups were 15.2 (95％CI: 12.576~17.842) and 16.1 (95％CI:13.988~18.234) months, respectively, with no significant difference (P>0.05). The quality of life (QOL) was improved in 2 cases (80%), kept stable in 6 cases (24.0%), and decreased in 17 cases (68.0%) in irinotecan treated group; the numbers in the endostar treated group were 12 (60.0%), 6 (30.0%), and 2 (10.0%), respectively, with significant difference between the two groups(P<0.01). The incidences of drugrelated adverse events, neutropenia and diarrhea, were higher in the irinotecan group than in the endostar group (P<0.01). Conclusion: Capecitabine combined with irinotecan or endostar are alternative therapies for oxaliplatinresistant patients with advanced colorectal cancer, and capecitabine combined with endostar is more effective and safe.
Keywords:
Project Supported:
Supported by the Medical Sciences Programe of Guangdong Province (No.A2008450)
Clc Number:
